ALKBH5 and hepatocellular carcinoma: Lastly, Wang et al. revealed ALKBH5 can reduce progestin and adipoQ receptor 4 (PAQR4) expression in an m6A-IGF2BP1 dependent manner, thereby suppressing the PI3K/AKT pathway activity and ultimately promoting HCC progression (Wang W. et al., 2023).